Track Twist Bioscience Corporation — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Twist Bioscience Corporation TWST Open Twist Bioscience Corporation in new tab

50.21 USD
EPS
-1.27
P/B
5.98
ROE
-16.79
Beta
2.29
Target Price
50.44 USD
Twist Bioscience Corporation logo

Twist Bioscience Corporation

🧾 Earnings Recap – Q1 2026

Twist Bioscience reported robust performance in Q1 of fiscal 2026, achieving its twelfth consecutive quarter of revenue growth with a 24% CAGR over the last three years, while significantly expanding its addressable market.

  • Revenue growth of 24% CAGR over the past three years, reflecting strong operational momentum.
  • Serviceable market expanded from $2 billion in 2020 to approximately $7 billion, with potential to exceed $12 billion by 2030.
  • Continued investment in AI-enabled therapeutics discovery led to over $25 million in orders booked, showcasing market leadership initiatives.
  • New product launches utilizing the semiconductor-based DNA synthesis platform are enhancing competitive positioning without increasing operational risk.
  • Strategic focus on expanding customer relationships and workflows in diagnostics and biopharma sectors is expected to drive sustained growth.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 4, 2026
EPS-1.27
Book Value7.44
Price to Book5.98
Debt/Equity24.79
% Insiders1.523%
Growth
Revenue Growth0.17%
Estimates
Forward P/E-23.62
Forward EPS-1.89
Target Mean Price50.44

DCF Valuation

Tweak assumptions to recompute fair value for Twist Bioscience Corporation (TWST)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Twist Bioscience Corporation Logo Twist Bioscience Corporation Analysis (TWST)

United States Health Care Official Website Stock

Is Twist Bioscience Corporation a good investment? Twist Bioscience Corporation (TWST) is currently trading at 50.21 USD. Market analysts have a consensus price target of 50.44 USD. This suggests a potential upside from current levels.

Earnings Schedule: Twist Bioscience Corporation is expected to release its next earnings report on May 4, 2026. The market consensus estimate for Forward EPS is -1.89.

Investor FAQ

Does Twist Bioscience Corporation pay a dividend?

No, it does not currently pay a dividend.

What asset class is Twist Bioscience Corporation?

Twist Bioscience Corporation is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be May 4, 2026. The company currently has a trailing EPS of -1.27.

Company Profile

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Exchange Ticker
NMS (United States) TWST
FRA (Germany) 0ME.F
MUN (Germany) 0ME.MU

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion